



(86) Date de dépôt PCT/PCT Filing Date: 2000/10/13

(87) Date publication PCT/PCT Publication Date: 2001/04/26

(85) Entrée phase nationale/National Entry: 2002/04/08

(86) N° demande PCT/PCT Application No.: US 2000/028636

(87) N° publication PCT/PCT Publication No.: 2001/029018

(30) Priorités/Priorities: 1999/10/15 (60/159,609) US;
2000/10/06 (09/684,046) US; 2000/10/06 (09/680,873) US

(51) Cl.Int.⁷/Int.Cl.⁷ C07D 307/54, A61K 31/343, A61P 9/06


(71) Demandeur/Applicant:
ARYX THERAPEUTICS, US

(72) Inventeurs/Inventors:
DRUZGALA, PASCAL, US;
MILNER, PETER G., US

(74) Agent: MBM & CO.

(54) Titre : NOUVEAUX COMPOSES ENANTIOMERES POUR LE TRAITEMENT DES ARYTHMIES CARDIAQUES ET
PROCEDES D'UTILISATION

(54) Title: NOVEL ENANTIOMERIC COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND METHODS
OF USE



(57) **Abrégé/Abstract:**

The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enantiomerically purified compounds, and compositions of these compounds, exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 April 2001 (26.04.2001)

PCT

(10) International Publication Number
WO 01/29018 A3(51) International Patent Classification⁷: C07D 307/54.
A61K 31/343, A61P 9/06(74) Agents: SALIWANCHIK, David, R. et al.; Saliwanchik,
Lloyd & Saliwanchik, Suite A-1, 2421 N.W. 41st Street,
Gainesville, FL 32606-6669 (US).

(21) International Application Number: PCT/US00/28636

(22) International Filing Date: 13 October 2000 (13.10.2000)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
60/159,609 15 October 1999 (15.10.1999) US
09/680,873 6 October 2000 (06.10.2000) US
09/684,046 6 October 2000 (06.10.2000) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*): ARYX
THERAPEUTICS [US/US]; 14690 Manuella Road, Los
Altos Hills, CA 94022 (US).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DRUZGALA,
Pascal [US/US]; 1609 Woodhue Avenue, Santa Rosa,
CA 95403 (US). MILNER, Peter, G. [US/US]; 14690
Manuella Road, Los Altos Hills, CA 94022 (US).(88) Date of publication of the international search report:
29 November 2001For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.(54) Title: NOVEL ENANTIOMERIC COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND METHODS
OF USE(57) Abstract: The subject invention pertains
to novel enantiomerically pure compounds, and
compositions comprising the compounds, for the
treatment of cardiac arrhythmias. The subject
invention further concerns a method of making and
purifying the compounds. The enantiomerically
purified compounds, and compositions of these
compounds, exhibit unexpectedly distinct and
advantageous characteristics, such as a markedly
superior ability to reduce or inhibit ventricular
premature beats, as compared to racemic mixtures
of the compounds.

WO 01/29018 A3

DESCRIPTIONNOVEL ENANTIOMERIC COMPOUNDS FOR TREATMENT OF CARDIAC
ARRHYTHMIAS AND METHODS OF USE

5

Cross-Reference to a Related Application

This application claims the benefit of U.S. Provisional Application No. 60/159,609, filed October 15, 1999.

10

Background of the Invention

Congestive heart failure (CHF) is a disease affecting approximately 2% of the population of the United States (Sami, M.H. [1991] *J. Clin. Pharmacol.* 31:1081). Despite advances in the diagnosis and treatment of CHF, the prognosis remains poor with a 5-year mortality rate higher than 50% from the time of diagnosis (McFate Smith, W. [1985] *Am. J. Cardiol.* 55:3A; McKee, P.A., W.P. Castelli, P.M. McNamara, W.B. Kannel [1971] *N. Engl. J. Med.* 285:1441). In patients with CHF, the rate of survival is lowest in those patients with severe depression of left ventricular function and patients who have frequent ventricular arrhythmias. Patients with ventricular arrhythmias and ischemic cardiomyopathy have an increased risk of sudden death. The presence of ventricular tachycardia in patients with severe CHF results in a three-fold increase in sudden death compared to those without tachycardia (Bigger, J.T., Jr. [1987] *Circulation* 75(suppl.IV):28). Because of the high prevalence of sudden unexpected death in patients with CHF, there has been a growing interest in the prognostic significance of arrhythmias in these patients.

20

25

30

Several compounds have been used in the management of cardiac arrhythmias in patients with congestive heart failure. Unfortunately, anti-arrhythmic drug therapy has been disappointing. The efficacy of anti-arrhythmic drugs markedly decreases as left ventricular function declines, such that only a small fraction of patients with CHF are responsive to anti-arrhythmic therapy. No anti-arrhythmic drug has prevented sudden death in patients with CHF and there is even a question of increased mortality associated with certain anti-arrhythmic drugs (the CAST investigators [1989] *N. Engl. J. Med.* 321:406).

Scientists define tachycardia and ventricular fibrillation as being of multiple nature. It now seems clear, and is accepted in the art, that re-entry is the underlying mechanism to most sustained arrhythmias. Prolonging ventricular repolarization as a means of preventing ventricular arrhythmias has consequently received renewed attention. This points to Class-III agents as drugs of choice in the treatment of arrhythmias. A Class-III agent, as referred to herein, is an agent which is classified as such in the Vaughan-Williams classification of anti-arrhythmic drugs. A Class-III agent exerts its primary anti-arrhythmic activity by prolonging cardiac action potential duration (APD), and thereby the effective refractory period (ERP), with no effect on conduction. These electrophysiological changes, which are brought about by blockade of cardiac potassium channels, are well known in the art. Because the blockade of cardiac potassium channels is not associated with depression of the contractile function of the heart, Class-III agents are particularly attractive for use in patients with CHF. Unfortunately, the existing Class-III agents are limited in their utility by additional pharmacological activities, lack of good oral bioavailability, or a poor toxicity profile. Two Class III agents currently marketed are bretylium (i.v. only) and amiodarone (i.v. and p.o.).

Amiodarone is an anti-arrhythmic agent with complex electrophysiological activity including Class-I (sodium channel), Class-II (beta-receptor), Class-III (potassium channel), and even Class-IV (calcium channel) properties, thus acting on both cardiac conduction and cardiac repolarization parameters (Charlier et al., [1969] *Cardiologia*, 54:82; Singh et al., [1970] *Br. J. Pharmacol.* 39:657; Rosenbaum et al., [1974] *Am. J. Cardiol.* 34:215; Rosenbaum et al., [1976] *Am. J. Cardiol.* 38:934). The corresponding EKG effects are reduction in heart rate (HR) and prolongation of the PR, QRS and QT intervals (Naccarelli et al., [1985] *Pharmacotherapy*, 6:298). Because of these combined electrophysiological properties, amiodarone is effective against ventricular and supra-ventricular arrhythmias, including atrial fibrillation and flutter, paroxysmal supraventricular tachycardia, ventricular premature beats (VPB), sustained and non-sustained ventricular tachycardia (VT), and ventricular fibrillation (VF) (Naccarelli et al., [1985] *Pharmacotherapy*, 6:298; Kerr et al., [1996], In *Cardiovascular Drug Therapy*, 2nd ed., Editor: Messerli, F.H. W.B. Saunders Co. pp. 1247 – 1264).

Amiodarone is one of the very few drugs that actually reduce mortality rates in high-risk patients (post-myocardial infarction patients and patients with congestive heart

failure)(Cairns et al., [1997] *Lancet*, 349:675; Julian et al., [1997] *Lancet*, 349:667; Amiodarone Trials Meta-Analysis Investigators: Effect of Prophylactic Amiodarone on Mortality After Acute Myocardial Infarction and in Congestive Heart Failure: Meta-Analysis of Individual Data from 6500 Patients in Randomised Trials. *Lancet*, 1997, 350, 1417 – 24). Unfortunately, because of its life-threatening side-effects and the substantial management difficulties associated with its use, amiodarone is indicated only for life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available anti-arrhythmics or when alternative agents are not tolerated (Vrobel et al., [1989] *Progr. In Cardiovasc. Dis.*, 31:393). The pharmacokinetic properties of amiodarone are characterized by slow absorption, moderate bioavailability, high lipophilicity, and a very large volume of distribution (60L/kg on average). Its elimination is almost exclusively hepatic and its clearance rate is very slow. Its terminal elimination half-life is 53 days (Naccarelli et al., [1985] *Pharmacotherapy*, 6:298). As a consequence, upon long-term administration, amiodarone accumulates in virtually every organ including poorly perfused tissues such as the lens. The onset of its anti-arrhythmic activity may take days, or even weeks to appear. The onset of activity can be shortened with the administration of intravenous loading doses, but is still too long (Kowey et al., [1995] *Circulation*, 92:3255). Cardioprotective agents and methods which employ amiodarone in synergistic combination with vasodilators and beta blockers have been described for use in patients with coronary insufficiency (U.S. Patent No. 5,175,187). Amiodarone has also been described for reducing arrhythmias associated with CHF as used in combination with anti-hypertensive agents, e.g., (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxyl]-L-proline (U.S. Patent No. 4,962,095) and zofenopril (U.S. Patent No. 4,931,464). However, amiodarone is a difficult drug to manage because of its numerous side effects, some of which are serious.

Amiodarone has several potentially fatal toxicities, the most important of which is pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis). Pulmonary toxicity is reversible if the progression of the symptoms is recognized on time, but is still fatal 10% of the time (Kerr et al., [1996], In *Cardiovascular Drug Therapy*, 2nd ed., Editor: Messerli, F.H. W.B. Saunders Co. pp. 1247 – 1264; Vrobel et al., [1989] *Progr. In Cardiovasc. Dis.*, 31:393). Liver injury is also common but usually

mild, although liver disease can occur and has been fatal in some cases. Even though toxicity is usually reversible upon cessation of drug administration, the real danger with amiodarone comes from its slow kinetics, especially slow elimination. For example, although the frequency of pro-arrhythmic events associated with amiodarone appears to be less than with other anti-arrhythmic agents (2 to 5%), the effects are prolonged when they occur. Even in patients at high risk of sudden death, in whom the toxicity of amiodarone is an acceptable risk, amiodarone poses major management problems that could be life-threatening, so every effort is made to utilize alternative agents first.

The most serious long-term toxicity of amiodarone derives from its kinetics of distribution and elimination. It is absorbed slowly, with a low bioavailability and relatively long half-life. These characteristics have clinically important consequences, including the necessity of giving loading doses, a delay in the achievement of full anti-arrhythmic effects, and a protracted period of elimination of the drug after its administration has been discontinued.

Amiodarone can also interact negatively with numerous drugs including aprindine, digoxin, flecainide, phenytoin, procainamide, quinidine, and warfarin. It also has pharmacodynamic interactions with catecholamines, diltiazem, propranolol, and quinidine, resulting in alpha- and beta-antagonism, sinus arrest and hypotension, bradycardia and sinus arrest, and torsades de pointes and ventricular tachycardias, respectively. There is also evidence that amiodarone depresses vitamin K-dependent clotting factors, thereby enhancing the anticoagulant effect of warfarin.

Numerous adverse effects limit the clinical applicability of amiodarone. Important side effects can occur including corneal microdeposits, hyperthyroidism, hypothyroidism, hepatic dysfunction, pulmonary alveolitis, photosensitivity, dermatitis, bluish discoloration, and peripheral neuropathy.

There is no Class-III agent presently marketed that can be used safely in patients with CHF. The cardiovascular drug market is the largest in any field of drug research, and an effective and safe Class-III anti-arrhythmic agent useful in patients with CHF is expected to be of substantial benefit. Therefore, a drug which could successfully improve the prognosis of CHF patients, but with a safety profile much improved over that of amiodarone, would be extremely useful and desired.

U.S. Patent Nos. 5,364,880; 5,440,054; and 5,849,788 (all to Druzgala) disclose novel anti-arrhythmic amiodarone analogs which are metabolized by esterases. The 2-butyl chain of amiodarone was functionalized to include an ester moiety, thus allowing endogenous esterases to metabolize the compounds into a primary metabolite containing a carboxylic acid moiety. Advantages associated with these compounds include smaller distribution volumes, shorter onset of activity, faster elimination rates, and safer long-term toxicity profiles. These amiodarone derivatives were synthesized as racemic mixtures.

The observed pharmacological activity of a given compound is the result of a complex interaction between its intrinsic activity at receptor level, its physical properties that determine transport through biological membranes, and its affinity toward metabolizing enzymes. As a result of this, it is practically impossible to predict differences in pharmacological activities between compounds that have very similar structures and similar physicochemical properties, such as optical isomers.

Biological systems however, because they are made of an assemblage of chiral subunits, are capable of recognizing optical isomers. The direct consequence of this chirality is often expressed by differences in receptor affinity, resulting in widely different pharmacological activities between optical isomers of the same drug. One of the most striking examples in the anti-arrhythmic field is the difference in pharmacological activity between *d*- and *l*-sotalol. Whereas *d*-sotalol is a class-III anti-arrhythmic, *l*-sotalol is a beta-blocker that is devoid of class-III properties. Clinical trials have demonstrated that neither *d*- nor *l*-sotalol alone are sufficient for efficient anti-arrhythmic activity in man, but that the mixture *d,l*-sotalol is required.

Brief Summary of the Invention

The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The isolated enantiomerically purified compounds and compositions of these compounds exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.

The enantiomerically pure compounds of the subject invention show differences at the kinetic and the dynamic levels that were totally unpredictable *a priori*. These pharmacological properties provide for the ability to reduce undesirable side effects associated with anti-arrhythmic drugs while maintaining a superior ability to modulate cardiac function in treatment regimens.

Brief Description of the Drawings

Figure 1 depicts amiodarone.

Figure 2 depicts the anti-arrhythmic activity of the test compounds R-2042, S-2042, and the racemate R,S-2042 by measuring their ability to inhibit the formation of extrasystoles or ventricular premature beats (VPB) when rats are challenged by an arrhythmogenic combination of benzene vapors and adrenaline.

Figure 3 demonstrates the anti-arrhythmic activity of the test compounds R-2055, S-2055, and the racemate R,S-2055 by measuring their ability to inhibit the formation of extrasystoles or ventricular premature beats (VPB) when rats are challenged by an arrhythmogenic combination of benzene vapors and adrenaline.

Figure 4 illustrates the change of heart rate in animals injected with adrenaline and the anti-tachyarrhythmic properties of test compounds R-2042, S-2042, and the racemate R,S-2042.

Figure 5 shows the change of heart rate in animals injected with adrenaline and the anti-tachyarrhythmic properties of test compounds R-2055, S-2055, and the racemate R,S-2055.

Figure 6 depicts the ability of test compounds R-2042, S-2042, and the racemate R,S-2042 to modulate the QT segment of EKG measurements.

Figure 7 demonstrates the ability of test compounds R-2055, S-2055, and the racemate R,S-2055 to modulate the QT segment of EKG measurements.

Figure 8 illustrates the ability of test compounds R-2042, S-2042, and the racemate R,S-2042 to modulate the QRS segment of EKG measurements.

Figure 9 shows the ability of test compounds R-2055, S-2055, and the racemate R,S-2055 to modulate the QRS segment of EKG measurements.

Figure 10 demonstrates the ability of test compounds R-2042, S-2042, and the racemate R,S-2042 to modulate the PR segment of EKG measurements.

Figure 11 depicts the ability of test compounds R-2055, S-2055, and the racemate R,S-2055 to modulate the PR segment of EKG measurements.

Figure 12 illustrates the plasma half-life of the compounds.

Figures 13A-B illustrates the synthesis pathways for R-2042 (10a), S-2042 (10b),
5 R-2055 (10c) and S-2055 (10d).

Figure 14 shows a generic structure covering compound S-2042.

Figure 15 shows a generic structure covering compound R-2055.

Figure 16 shows a generic structure covering compound R-2042.

Figure 17 shows a generic structure covering compound S-2055.

10 **Figure 18** shows the structure of S-2042.

Figure 19 shows the structure of R-2055.

Figure 20 shows the structure of R-2042.

Figure 21 shows the structure of S-2055.

15 Detailed Disclosure of the Invention

The subject invention pertains to enantiomerically isolated compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making and purifying the compounds. The isolated enantiomerically pure compounds, and compositions of these compounds,
20 exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats as compared to racemic mixtures of the compounds.

The isolated enantiomeric forms of the compounds of the invention are substantially free from one another (i.e., in enantiomeric excess). In other words, the “R”
25 forms of the compounds are substantially free from the “S” forms of the compounds and are, thus, in enantiomeric excess of the “S” forms. Conversely, “S” forms of the compounds are substantially free of “R” forms of the compounds and are, thus, in enantiomeric excess of the “R” forms. In one embodiment of the invention, the isolated enantiomeric compounds are at least about in 80% enantiomeric excess. In a preferred
30 embodiment, the compounds are in at least about 90% enantiomeric excess. In a more preferred embodiment, the compounds are in at least about 95% enantiomeric excess. In an even more preferred embodiment, the compounds are in at least about 97.5%

enantiomeric excess. In a most preferred embodiment, the compounds are in at least about 99% enantiomeric excess.

The improved properties, or characteristics, of the compounds of the subject invention provide for improved methods of treating cardiac arrhythmias by administering the compounds of the invention to an individual in need of treatment. One or more compounds of the invention may be administered to an individual. Furthermore, the compounds of the invention may be administered in conjunction with other compounds, or compositions thereof. These compounds, and compositions thereof, may include other compounds known to be useful for the treatment of cardiac arrhythmias, cardioprotective agents, antibiotics, antiviral agents, or thrombolytic agents (e.g., streptokinase, tissue plasminogen activator, or recombinant tissue plasminogen activator).

The compounds and compositions of the invention can have particular usefulness for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). Post-myocardial infarction patients can also particularly benefit from the administration of the subject compounds and compositions; thus, methods of treating post-myocardial infarction patients are also provided by the subject invention. An "individual" includes animals and humans in need of treatment for arrhythmias. In a preferred embodiment, the individual is a human.





Cardioprotective agents include vasodilators and beta blockers described for use in patients with coronary insufficiency (such as those of U.S. Patent No. 5,175,187 or others known to the skilled artisan). Other cardioprotective agents include known anti-hypertensive agents, e.g., (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxyl]-L-proline (U.S. Patent No. 4,962,095) and zofenopril (U.S. Patent No. 4,931,464). Additional cardioprotective agents include, but are not limited to, aspirin, heparin, warfarin, digitalis, digitoxin, nitroglycerin, isosorbide dinitrate, hydralazine, nitroprusside, captopril, enalapril, and lisinopril.

The compounds and compositions also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways. Compounds and compositions of the invention are also useful for the treatment of ventricular and supra-ventricular arrhythmias, including atrial fibrillation and flutter, paroxysmal supraventricular tachycardia, ventricular premature beats (VPB), sustained and non-sustained ventricular

tachycardia (VT), and ventricular fibrillation (VF). Other non-limiting examples of the arrhythmias which may be treated by the compounds of the instant invention include: narrow QRS tachycardia (atrial, intra- /para- A-V node, or accessory pathway), ventricular tachycardia, and ventricular arrhythmias in cardiomyopathy.

Thus, the subject invention represents an innovative improvement of a Class-III anti-arrhythmic agent having significantly lower toxicity than any currently available compound. The compounds and compositions are useful for treating patients with congestive heart failure (CHF) and exhibit fewer undesirable properties as compared to racemic mixtures of the compounds.

Thus, the invention provides isolated enantiomeric compounds of the formulae:



wherein

X_1 and X_2 may be the same or different and are selected from the group consisting of iodine, fluorine, bromine, and chlorine;

5 R_1 , R_2 , and/or R_3 is a moiety selected from the group consisting of H, C_{n-20} alkyl, C_{2-20} alkenyl, aryl, C_{1-20} alkyl-aryl, C_{2-20} alkenyl-aryl, heteroaryl, C_{1-20} alkyl-heteroaryl, C_{2-20} alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C_{1-20} alkyl-heterocycloalkyl, and C_{1-20} alkyl-cycloalkyl, any of which may be, optionally, substituted with moiety selected from the group consisting of C_{1-6} alkyl, halogen, CN, NO_2 , and SO_{2-4} .

10 In accordance with the subject invention, m may be from 0 to 10. In a preferred embodiment, m is 4. In another preferred embodiment, m is 3. In a more preferred embodiment, m is 2. In an even more preferred embodiment, m is 0. In the most preferred embodiment, m is 1.

15 As used in this specification the term " C_{n-20} alkyl" refers to straight or branched chain alkyl moiety having up to twenty carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and the like. The value for n may be from 1 to 19. In one embodiment, n is 1, in a preferred embodiment, n is 2.

20 The term " C_{2-20} alkenyl" refers to a straight or branched chain alkyl moiety having two to twenty carbon atoms and having in addition at least one double bond. This term includes for example, vinyl, 1-propenyl, 1- and 2-butenyl, 2-methyl-2-propenyl, etc.

The term "cycloalkyl" refers to a saturated alicyclic moiety having from three to six carbon atoms and which is optionally benzofused at any available position. This term includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, indanyl and tetrahydronaphthyl.

25 The term "heterocycloalkyl" refers to a saturated heterocyclic moiety having from three to six atoms including one or more heteroatoms selected from N, O, S and oxidized versions thereof, and which is optionally benzofused at any available position. This term includes, for example, azetidiny, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, indolinyl and tetrahydroquinolinyl.

30 The term "cycloalkenyl" refers to an alicyclic moiety having from three to six carbon atoms and having in addition at least one double bond. This term includes, for example, cyclopentenyl and cyclohexenyl.

The term "heterocycloalkenyl" refers to an alicyclic moiety having from three to six atoms and one or more heteroatoms selected from N, O, S and oxidized versions thereof, and having in addition at least one double bond. This term includes, for example, dihydropyranyl.

5 The term "aryl" refers to an aromatic carbocyclic radical having a single ring or two condensed rings. This term includes, for example phenyl or naphthyl.

The term "heteroaryl" refers to an aromatic ring system of five to ten atoms of which at least one atom is selected from O, N and S, and includes, for example, furanyl, thiophenyl, pyridyl, indolyl, quinolyl and the like.

10 The term "cycloimidyl" refers to a saturated ring of five to ten atoms containing the atom sequence $-C(=O)NC(=O)-$. The ring may be optionally benzofused at any available position. Examples include succinimidoyl, phthalimidoyl and hydantoinyl.

The term "benzofused" refers to the addition of a benzene ring sharing a common bond with the defined ring system.

15 The term "optionally substituted" means optionally substituted with one or more of the groups specified, at any available position or positions.

The term "halogen" means fluorine, chlorine, bromine or iodine.

The subject invention also provides compositions containing the compounds of the invention in pharmaceutically acceptable carriers. The compounds of the subject invention can be formulated according to known methods for preparing pharmaceutically useful compositions. Formulations are described in detail in a number of sources which are well known and readily available to those skilled in the art. For example, *Remington's Pharmaceutical Science* by E.W. Martin describes formulations which can be used in connection with the subject invention. In general, the compositions of the subject invention will be formulated such that an effective amount of the bioactive compound(s) is combined with a suitable carrier in order to facilitate effective administration of the composition.

20
25

In one aspect, the subject invention provides pharmaceutical compositions comprising, as an active ingredient, an effective amount of one or more of the compounds and one or more non-toxic, pharmaceutically acceptable carriers or diluents. Examples of such carriers for use in the invention include ethanol, dimethyl sulfoxide, glycerol, silica, alumina, starch, and equivalent carriers and diluents.

30

Further, acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories and dispersible granules. A solid carrier can be one or more substances which may act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet
5 disintegrating agents or an encapsulating material.

The disclosed pharmaceutical compositions may be subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, such as packeted tablets, capsules, and powders in paper or plastic containers or in vials or ampules. Also, the unit dosage can be a liquid based
10 preparation or formulated to be incorporated into solid food products, chewing gum, or lozenges.

The dosage administered to an individual will be dependent upon the response desired and may be dependent upon the type of host involved, its age, health, weight, kind of concurrent treatment, if any; frequency of treatment; therapeutic ratio and like
15 considerations. Advantageously, dosage levels of the administered active ingredients can be, for examples, dermal, 1 to about 500 mg/kg; orally, 0.01 to 200 mg/kg; intranasal 0.01 to about 100 mg/kg; and aerosol 0.01 to about 50 mg/kg of body weight.

Expressed in terms of concentration, the isolated enantiomeric forms of the invention can be present in the new compositions for use dermally, intranasally, bronchially, intramuscularly, intravaginally, intravenously, or orally in a concentration
20 of from about 0.01 to about 50% (w/w) of the composition, and especially from about 0.1 to about 30% (w/w) of the composition. Preferably, the isolated enantiomeric forms of the compounds are present in a composition from about 1 to about 10% (w/w). In one embodiment, the composition comprises about 5% (w/w) of the isolated enantiomeric
25 compound.

In other embodiments, the compounds of the subject invention are administered intravenously and/or orally. Initial oral "loading doses" are, typically, administered over the course of one to three weeks. The loading doses may be administered over longer or shorter time frames and are administered until an initial therapeutic effect is observed.
30 Typically, individual patient titration is performed for the administration of the subject compounds (*i.e.*, the therapeutic regimen is tailored to a specific patient).

The following dosage ranges represent suggested guidelines for the oral and intravenous administration of the subject compounds to an individual. Initial loading doses range between 100 and 5000 mg per day, preferably between 250 and 4000 mg per day, more preferably between 400 and 3000 mg per day, even more preferably between 600 and 2000 mg per day, and most preferably between 700 and 1600 mg per day.

After adequate arrhythmia control is established, the dosage of the compounds of the subject invention may be reduced over the course of about one month. Dosages administered over this time frame are between 100 and 1600 mg per day, preferably between 200 and 1400 mg per day, more preferably between 300 and 1200 mg per day, even more preferably between 400 and 1000 mg per day, and most preferably between 600 and 800 mg per day. After this reduction in compound dosage, individuals are typically maintained on compound dosages of about 400 mg per day (the maintenance dosage). Because control of arrhythmias is patient specific, some maintenance dosages may be higher or lower than the typical maintenance dosage. Thus, maintenance dosages can range between 50 and 800 mg per day, preferably between 100 and 700 mg per day, even more preferably 200 and 600 mg per day, and most preferably between 300 and 500 mg per day.

The invention also provides for salts of the disclosed compounds. Salts of the compounds include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, p-toluenesulfonates, phosphates, sulfates, perchlorates, acetates, trifluoroacetates, propionates, citrates, malonates, succinates, lactates, oxalates, tartrates, and benzoates. Salts may also be derived from bases (organic and inorganic), such as alkali metal salts (e.g., magnesium or calcium salts), or organic amine salts, such as morpholine, piperidine, dimethylamine, or diethylamine salts.

Table 1 provides the electrophysiological activities of the individual enantiomers as compared to each respective racemate. The descriptors "longer", "shorter", "higher", "lower", or "no change" describe the electrophysiological effects of the isolated enantiomers as compared to the respective racemate. This table summarizes the data provided in Examples 3-6 and Figures 2-12.

Table 1				
	R-2042	S-2042	R-2055	S-2055
	Inhibition of VPB	longer	longer	longer
	Number of VPB	lower	lower	lower
5	Inhibition of tachycardia	longer	longer	longer
	Heart rate (beats/minute)	lower	lower	lower
	QT interval	no change	longer	no change
	QRS interval	no change	longer	longer
	PR interval	shorter	longer	shorter
10	Plasma half-life (hours)	5.0	7.3	11.7
		8.8		

All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety to the extent that the reference is not inconsistent with the teachings provided herein. Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1 – Anti-arrhythmic activity in anesthetized rats.

Male Sprague-Dawley rats with body weights of 410 ± 30 g (Harlan Sprague Dawley Inc., Indianapolis, IN), were anesthetized with sodium pentobarbital (50 mg/kg i.p. - Butler Co., Columbus, OH). The skin from the neck area was removed and the jugular veins on both sides were cleared of connective tissue. Both jugular veins and the left carotid artery were isolated, and the latter tied up cranially with a surgical silk (ETHICON 4-0, Ethicon Inc., Australia). A plastic catheter (INTRACATH 19ga, Vecton Dickinson, Sandy, UT), filled with a solution containing 10% sodium heparin (Elkins-Sinn Inc., Cherry Hill, NJ) in normal saline (100 U/ml sodium heparin), was introduced into the artery and fixed with surgical silk.

The catheter was connected to a pressure transducer (OHMEDA P23-XL, Ohmeda Medical Devices Division Inc., Madison, WI), filled with the same heparinized 0.9% NaCl solution, to register beat-to-beat arterial pressure. Needle electrodes were

inserted s.c., and together with the pressure transducer, were joined to a GOULD TA 2000 recorder. Leads II, aVF and intraarterial blood pressure were monitored simultaneously throughout the experiments and recorded at certain intervals at 50 and 200 mm/sec paper speed.

5 The surgery was completed with an incision on the trachea where a short plastic tubing was placed and the animal was connected to a rodent-model ventilator (HARVARD Model 683, Harvard Apparatus, Inc., Holliston, MA). The animals were ventilated in a controlled way, depending on their spontaneous breathing frequency (55-75/min).

10 Drug administrations were carried out through i.v. catheters (TERUMO 24 GA*3/4", Terumo Medical Corp., Elkton, MD) inserted into both jugular veins. The left side was used for drug infusions by means of a syringe pump (SAGE INSTRUMENTS, Model 341B, Orion Res. Inc., Boston, MA), and the right side was used for adrenaline injections. The experiments were started after at least 15 minutes of stabilization.

15 Benzene/adrenaline challenges were performed as follows: the respirator inlet was connected to a 50-ml bubbler half-full with benzene (Fisher Scientific, Fair Lawn, NJ) so that the inspired air was saturated with benzene vapor. The animal was ventilated with benzene vapor for two minutes. The tidal volume was typically 1 ml/100g of animal. During the last 30 seconds of benzene ventilation, 10 μ g/kg adrenaline solution (in 0.9% NaCl) was injected into the right jugular vein. Typically, within 30 seconds, ventricular premature beats (VPB) and hemodynamically stable sustained and non-sustained repetitive rhythm returned and the animal did not show other abnormal signs. These arrhythmias could be elicited repeatedly. After three control VTs (at -30, -20 and -10 minutes), the test compounds were injected slowly during 30 seconds at a dose of 4

20 mg/kg i.v., immediately followed by a slow infusion of 12 mg/kg/h for 2 hours. The flow rate during the infusion period was 1 ml/h.

There were 5 rats per test compound and each animal served as its own control. The ability of the different drugs to suppress arrhythmias was tested against repeated benzene/adrenaline challenges at 5, 15, 30, 45, 60, 90, 120 (end of drug infusion), 135,

30 150, 165 and 180 minutes after the i.v. bolus injection. The amplitudes of the systolic arterial pressure and diastolic arterial pressure were DBP/3+DBP with the help of a pressure-amplitude calibration curve. Heart rate, number of ventricular complexes during

the occurrence of VTs and VPBs, and certain ECG parameters (PR, QRS, QT durations and RR cycle lengths in msec) were also recorded and measured manually. At each time-point, 3-5 cycles were measured and the average values were entered into EXCEL Windows 97. The average and standard deviation for the five experimental animals per compound were calculated. Results are shown in Figures 2-11.

Example 2 – Half-life in human plasma *in vitro*.

Venous blood (60 ml) was collected in heparinized 15-ml Vacutainer® tubes from the forearm of five human volunteers. Each tube contained 1,000 units of heparin sodium salt. The blood was immediately centrifuged at 2,000 g for 10 minutes and the plasma was collected. Immediately after collection, the plasma was divided into 2-ml aliquots in borosilicate glass tubes (5-ml capacity) capped with a plastic stopper. The tubes were then equilibrated in a 37°C-water bath for at least 15 minutes before the test samples were added.

Stock solutions were prepared by dissolving 25 μ moles (about 18 mg) of each of the test compounds in 10 ml of deionized water. To each of the glass tubes containing 2 ml of fresh plasma, equilibrated at 37°C, was added 40 μ l of the stock solutions (one test compound per tube). The plasma/stock solutions were then mixed. Samples (250 μ l) were collected at time 0 (immediately after mixing test compounds in plasma) and then at 30, 60, 90, 120, 180, 240, and 300 minutes. The test tubes were capped, to avoid concentration due to evaporation, and left in the 37°C bath during the entire experiment. Each aliquot was immediately introduced into a 1.5-ml microfuge tube containing 20 μ l of a 0.01% solution of diethyl paranitrophenylphosphate (paraoxon) in ethanol in order to inhibit esterase activity. The tubes were then capped and vortexed, then kept at -20°C until analysis. The samples were thawed and mixed with 750 μ l of a 0.1% solution of trifluoroacetic acid (TFA) in acetonitrile, vortexed for thorough mixing, and then centrifuged at 12,000 g for 15 minutes. The supernatant was collected for injection in the HPLC system.

The HPLC mobile phase consisted of acetonitrile and water containing 0.1% TFA and 400 mg/L benzyltriethylammonium chloride (BTEAC) in the following proportions and flow rates: 85% acetonitrile and 15% water at 2.0 ml/min. The detection wavelength was set at 242 nm, and the injected volume was 100 μ L. The HPLC peaks were

recorded, and the integrated values were plotted against time using the SIGMAPLOT software version 4.0 for WINDOWS. The resulting curves were fitted to a first-order exponential decay equation from which hydrolysis half-lives were calculated. Half-life in human plasma is shown in Figure 12.

5

Example 3 – ATI-2042: Electrophysiological properties in anesthetized rats.

In anesthetized rats, there is a marked difference in pharmacological activity between R-2042, S-2042, and the racemate R,S-2042. In Figure 2, we measured the anti-arrhythmic activity of the test compounds by measuring their ability to inhibit the formation of extrasystoles or ventricular premature beats (VPB) when the rats were challenged by an arrhythmogenic combination of benzene vapors and adrenaline. While S-2042 totally inhibited the formation of ventricular premature beats for the whole period of drug administration (time 0 to 120 min) and still retained part of its activity at the end of the washout period (time 180 min), R-2042 loses activity much sooner (around time 100 min) and is completely inactive at the end of the washout period. The racemate R,S-2042 is even less active than either the R- or the S-isomer.

Figure 4 shows how the heart rate suddenly increases from 320 beats per minute (bpm) to between 500 and 600 bpm when the rats are injected with adrenaline. When ATI-2042 is administered from time 0 to time 120 minutes, we observe a very good protection against this tachyarrhythmia. However, as in Figure 2, S-2042 is more potent and longer acting than R-2042, the racemic mixture R,S-2042 being the least potent and shortest acting. The same trend is observed in Figures 6, 8, and 10.

In Figure 6, we see the effects of ATI-2042 on the QT segment of the EKG recording. This QT segment is a measure of the Class-III properties (potassium-channel blocking and increase in refractoriness) of the compounds. Again, R-2042, S-2042, and R,S-2042 show 3 different profiles of activity, S-2042 being the most potent and the longest acting. Figure 8 shows the activity on the QRS segment of the EKG recording which measures the Class-I activity (sodium-channel blocking and decreased conduction rate). Here again, the previous pattern between the individual isomers and the racemate is conserved.

Finally, in Figure 10, we see the effects on the PR segment of the EKG recording, which measures the Class-IV activity of the compounds (calcium-channel blocking and

decreased AV conduction). Again, we see that in this model, S-2042 is much more potent than R-2042 and the racemate R,S-2042.

Example 4 – Half-life in human plasma *in vitro*.

5 ATI-2042 is metabolized in human plasma by esterase enzymes. The half-life of the R-isomer is 5.0 hours whereas the S-isomer has a half-life of 7.3 hours, a substantial difference. The R-isomer is not always the most rapidly metabolized isomer in the ATI-2000 series (see Figure 12).

10 Example 5 – ATI-2055: Electrophysiological properties in anesthetized rats.

 In anesthetized rats, there were also differences in pharmacological activity between R-2055, S-2055, and the racemate R,S-2055. We measured the anti-arrhythmic activity of the test compounds by measuring their property to inhibit the formation of extrasystoles or ventricular premature beats (VPB) when the rats are challenged by an
15 arrhythmogenic combination consisting of benzene vapors and adrenaline. While R-2055 totally inhibited the formation of ventricular premature beats for the whole period of drug administration (time 0 to 120 min) and still retained part of its activity at the end of the washout period (time 180 min), we see that S-2055 loses activity much sooner (about time 40 min) and is completely inactive at the end of the washout period. The racemate
20 R,S-2055 is even less active than either the R-2055 or the S-2055 enantiomer (see Figure 3). These differences in activity could not be predicted.

 ATI-2055 inhibits the tachycardia (increased heart rate) produced by the injection of adrenaline. Whereas, the racemate R,S-2055 has a more potent effect than either R-2055 or S-2055, its effects wear off more rapidly, starting at about 50 minutes. Both
25 R-2055 and S-2055 have similar potency, but R-2055 has a longer-lasting effect than S-2055 (see Figure 5). Thus, using either of the enantiomers is preferable to using the racemate where a longer duration of action is a desired therapeutic effect.

 A similar trend is observed with the QT interval; the racemate is more potent than either one of the enantiomers, however, its duration of action is shorter (see Figure 7).
30 All three forms increase the QRS interval to a similar degree of potency, but again, the racemate has a shorter duration of action (see Figure 9). All three forms also increase the P,R interval (see Figure 11). The potency of the racemate is higher than would be

expected from the potencies of the individual enantiomers, and this synergistic effect is a strong indication that the R- and S- enantiomers act at different calcium channel sites.

Example 6 – Half-life of ATI-2055 in human plasma *in vitro*.

ATI-2055 is metabolized in human plasma by esterase enzymes (Figure 12). The half-life of the R-isomer is 11.7 hours whereas the S-isomer has a half-life of 8.8 hours, a substantial difference. This is different from ATI-2042 where the R-isomer had a shorter half-life than the S-isomer and demonstrates the unpredictability associated with the relative enzymatic hydrolysis rates for the individual isomers of a chiral molecule.

Example 7 – Isolation/Production of ATI-2042 and ATI-2055 R and S Enantiomers.

2-acetylbenzofuran (2). Potassium carbonate (588 g, 4.25 mol), acetone (1,000 ml), and salicylaldehyde (504 g, 4.13 mol) were introduced into a 5-liter 3-necked flask fitted with a mechanical stirrer, an addition funnel, and an efficient reflux condenser. Chloroacetone (388 g, 4.19 mol) was added slowly over a period of 60 minutes at such a rate that the reaction temperature never went out of control (a mild reflux was achieved after 30 minutes of chloroacetone addition). After the addition was complete, a mild reflux was maintained for another 120 minutes. The reaction was then allowed to cool down to room temperature and was filtered into another 5-liter flask. The potassium carbonate cake was washed with acetone (100 ml) and the solvent was evaporated. The crude product weighed 602g and was used as such in the next step. The product was purified by vacuum distillation (bp 80°/1 mm). The pure product solidified as white needles melting at 71-72°C. Anal. (C₁₀H₈O₂) C, H: calculated 74.99, 5.03; found 74.95, 5.04.

2-benzofurylthioacetomorpholide (3). 2-Acetylbenzofuran (488 g, 3.05 mol), sulfur powder (98 g, 3.06 mol), and morpholine (285 g, 3.27 mol) were introduced into a 3-liter 3-necked flask fitted with a reflux condenser, a thermometer, and a mechanical stirrer. The mixture was brought to a gentle reflux (126-128°C) for 60 minutes and the bath temperature was then increased by 10°C and kept at this temperature for a total of 8 hours. The reaction was cooled down to below 60°C and methanol (400 ml) was added. The product (491 g, 1.88mol, 62% yield) precipitated as a black solid that was isolated by filtration and used directly in the next step without further identification.

Benzofuran-2-acetic acid (4). The thiomorpholide **3** (490g, 1.88mol) was dissolved in 12N HCl (1,000ml) and acetic acid (500ml). The solution was stirred at reflux temperature for 18 hours. The progress of the reaction was monitored by TLC on silica plates, eluting with methanol/dichloromethane (5:95 v/v). The solvent was evaporated. The product was stirred with cold 1N HCl and filtered with suction and the filtration cake was washed several times with 100-ml portions of 1N HCl, and air-dried for 2 hours. The crude acid was dried at 40°C in a vacuum oven overnight until constant weight. The crude product weighed 308 g (1.74 mol, 93% yield). An analytical sample was purified on silica (CH₂Cl₂/MeOH 5:95) to give a white solid melting at 98.5-99.5°C. Anal. (C₁₀H₈O₃) C, H: calculated 68.18, 4.58; found 68.16, 4.57.

Methyl benzofuran-2-acetate (5). Benzofurane-2-acetic acid **4** (305g, 1.73 mol) was dissolved in methanol (1,000ml) and concentrated sulfuric acid (20 ml). The mixture, which was originally a suspension, was stirred at reflux for 120 minutes. Half of the methanol was distilled off and a mixture consisting of water, KOH, and ethyl acetate (2,000ml/65g/1,000ml) was added. After mixing well, the organic layer was allowed to separate and was isolated. The aqueous phase was extracted once more with ethyl acetate (500ml) and the combined organic extracts were dried over sodium sulfate, filtered, and evaporated. The crude product was a reddish oil weighing 316 g, which was purified by flash vacuum distillation at 0.1 mm Hg (bp 80-90°C). The yield of distilled product, a colorless oil, was 288g (1.51mol, 86%). Anal. (C₁₁H₁₀O₃) C, H: calculated 69.46, 5.30; found 69.49, 5.36.

Methyl 2-[3-(4-methoxybenzoyl)]benzofuraneacetate (6). The distilled ester **5** (278 g, 1.46 mol), para-anisoyl chloride (248.5 g, 1.46 mol), and anhydrous dichloroethane (800 ml) were added to a 3-liter 3-necked flask fitted with an ice-bath, a mechanical stirrer, an addition funnel, and a thermometer. Tin (IV) chloride (380g, 1.46mol) was added in several portions and the mixture was stirred at room temperature under nitrogen for 18 hours. Another portion of dichloroethane (1,200 ml) was added and the solution was poured onto ice. The organic phase was separated and washed again with water, then with a 3% sodium bicarbonate solution, and then again with water. The organic solution was then dried over sodium sulfate, filtered, and the solvent was evaporated. The crude product was stirred in hexane for 24 hours to give an off-white solid that was isolated by filtration and dried. The yield was 366 g (1.13mol, 77%). A

sample (1 g) was purified by column chromatography on silica gel and crystallized from ethyl acetate/hexane. The analytical sample had a melting point of 76.8-77.2°C. Anal. (C₁₉H₁₆O₅) C, H: calculated 70.35, 4.98; found 70.46, 5.01.

2-[3-(4-Hydroxybenzoyl)]benzofuraneacetic acid (7). Ester **6** (360g, 1.13mol), anhydrous acetonitrile (2.5L), and anhydrous toluene (5L) were introduced into a 20L flask fitted with an efficient reflux condenser, a mechanical stirrer, and a nitrogen inlet. To this was added, while stirring, aluminum iodide (1.5kg, 3.67mol) in several portions, then tetrabutylammonium iodide (10g, catalytic amount). The mixture was then stirred at reflux under nitrogen for 3 hours and the reaction was allowed to cool down to room temperature. Water (1,300ml) was then added slowly, followed by ethyl acetate (2.5L). The mixture was then pumped through an in-line filter containing celite, the organic phase was separated, dried over sodium sulfate, and evaporated, to give 285g (0.96mol, 85%) of a dark solid that showed one major spot on TLC (silica, ethyl acetate/methanol 90:10). Anal. (C₁₇H₁₂O₅) C, H: calculated 68.92, 4.08; found 68.93, 4.10.

2-[3-(3,5-Diiodo-4-hydroxybenzoyl)]benzofuraneacetic acid (8). To compound **7** (280g, 0.96mol) in water (5L) was added potassium carbonate (369g, 2.88mol) and iodine beads (487g, 1.92mol). The mixture was stirred at room temperature overnight and was washed with ethyl acetate (3x1,000ml). To the aqueous phase was then added another portion of ethyl acetate (2.5L) and, slowly, 12N HCl, until the pH of the aqueous phase was about 2.0. The organic phase was then isolated and dried over sodium sulfate. Most of the solvent (80%) was evaporated, and the flask was cooled to between 0 and 4°C and left at that temperature for 4 hours. The product, a tan solid, was isolated by filtration and was washed with minimum amount of cold ethyl acetate until the color was pale yellow. More product could be isolated by evaporating the filtrate to dryness and triturating the dark residue with cold ethyl acetate. The yield was 431g (0.79mol, 82%). Mp. 174-176°C. Anal. (C₁₇H₁₀O₅I₂) C, H, I: calculated 37.26, 1.84, 46.41; found 37.44, 1.95, 46.28.

(R)-sec-Butyl 2-[3-(3,5-diiodo-4-hydroxybenzoyl)]benzofuraneacetate (9a). Compound **8** (8.2g, 15mmol) was dissolved in (R)-2-butanol (50ml). Sulfuric acid (0.5ml) was added, and the mixture was stirred at reflux for 2 hours. The solvent was evaporated and the residue was partitioned between ethyl acetate (50ml) and 10% sodium bicarbonate solution (100ml). The organic phase was dried over sodium sulfate. The

yield was 7.76g (13.8mmol, 92%) of a thick oil. The product was purified by chromatography on silica (CH₂Cl₂/MeOH 98:2). Anal. (C₂₁H₁₈O₅I₂) C, H, I: calculated 41.75, 3.00, 42.01; found 41.71, 3.02, 41.96.

(S)-sec-Butyl 2-[3-(3,5-diiodo-4-hydroxybenzoyl)]benzofuraneacetate (9b).

5 Compound **8** (8.2g, 15mmol) was dissolved in (S)-2-butanol (50ml). Sulfuric acid (0.5ml) was added, and the mixture was stirred at reflux for 2 hours. The solvent was evaporated and the residue was partitioned between ethyl acetate (50ml) and 10% sodium bicarbonate solution (100ml). The organic phase was dried over sodium sulfate. The yield was 7.76g (13.8mmol, 92%) of a thick oil. The product was purified by
10 chromatography on silica (CH₂Cl₂/MeOH 98:2). Anal. (C₂₁H₁₈O₅I₂) C, H, I: calculated 41.75, 3.00, 42.01; found 41.77, 3.05, 41.89.

(R) - (3 - M e t h y l) - 2 - b u t y l 2 - [3 - (3 , 5 - d i i o d o - 4 - hydroxybenzoyl)]benzofuraneacetate (9c).

Compound **8** (8.2g, 15mmol) was dissolved in (R)-3-methyl-2-butanol (50ml). Sulfuric acid (0.5ml) was added, and the
15 mixture was stirred at reflux for 2 hours. The solvent was evaporated and the residue was partitioned between ethyl acetate (50ml) and 10% sodium bicarbonate solution (100ml). The organic phase was dried over sodium sulfate. The yield was 7.76g (13.8mmol, 92%) of a thick oil. The product was purified by chromatography on silica (CH₂Cl₂/MeOH 98:2). Anal. (C₂₂H₂₀O₅I₂) C, H, I: calculated 42.74, 3.26, 41.06; found 42.68, 3.21, 40.97.

(S) - (3 - M e t h y l) - 2 - b u t y l 2 - [3 - (3 , 5 - d i i o d o - 4 - hydroxybenzoyl)]benzofuraneacetate (9d).

Compound **8** (8.2g, 15mmol) was dissolved in (S)-3-methyl-2-butanol (50ml). Sulfuric acid (0.5ml) was added, and the
20 mixture was stirred at reflux for 2 hours. The solvent was evaporated and the residue was partitioned between ethyl acetate (50ml) and 10% sodium bicarbonate solution (100ml). The organic phase was dried over sodium sulfate. The yield was 7.76g (13.8mmol, 92%)
25 of a thick oil. The product was purified by chromatography on silica (CH₂Cl₂/MeOH 98:2). Anal. (C₂₂H₂₀O₅I₂) C, H, I: calculated 42.74, 3.26, 41.06; found 42.64, 3.29, 41.17.

(R) - s e c - B u t y l 2 - [3 - (3 , 5 - d i i o d o - 4 - (2 - diethylaminoethoxy)benzoyl)]benzofurane-acetate (10a).

Compound **9a** (6.9g, 12.3mmol) was dissolved in CH₂Cl₂ (50ml) and was added to a solution of diethylaminoethyl chloride, hydrochloride (2.55g, 14.8mmol) and
30 benzyltriethylammonium chloride (0.28g, 1.23mmol) in water (50ml). The biphasic

medium was stirred vigorously and a 1N NaOH solution (27ml) was added slowly. After stirring for another 4 hours, the organic phase was isolated and dried over sodium sulfate. The product was purified on silica (CH₂Cl₂/MeOH 98:2 then 98:4). The yield was 6.43g (9.72mmol, 79%) of a thick greenish oil. Anal. (C₂₇H₃₁I₂NO₅) C, H, N, I: calculated 46.11, 4.44, 1.99, 36.09; found 46.13, 4.42, 2.00, 36.12.

(S) - sec - Butyl 2 - [3 - (3 , 5 - diiodo - 4 - (2 - diethylaminoethoxy)benzoyl)]benzofurane-acetate (10b). Compound 9b (6.9g, 12.3mmol) was dissolved in CH₂Cl₂ (50ml) and was added to a solution of diethylaminoethyl chloride, hydrochloride (2.55g, 14.8mmol) and benzyltriethylammonium chloride (0.28g, 1.23mmol) in water (50ml). The biphasic medium was stirred vigorously and a 1N NaOH solution (27ml) was added slowly. After stirring for another 4 hours, the organic phase was isolated and dried over sodium sulfate. The product was purified on silica (CH₂Cl₂/MeOH 98:2 then 98:4). The yield was 6.43g (9.72mmol, 79%) of a thick greenish oil. Anal. (C₂₇H₃₁I₂NO₅) C, H, N, I: calculated 46.11, 4.44, 1.99, 36.09; found 46.18, 4.46, 2.05, 36.19.

(R) - (3 - Methyl) - 2 butyl 2 - [3 - (3 , 5 - diiodo - 4 - (2 - diethylaminoethoxy)benzoyl)]benzo-furaneacetate (10c). Compound 9c (6.9g, 12.3mmol) was dissolved in CH₂Cl₂ (50ml) and was added to a solution of diethylaminoethyl chloride, hydrochloride (2.55g, 14.8mmol) and benzyltriethylammonium chloride (0.28g, 1.23mmol) in water (50ml). The biphasic medium was stirred vigorously and a 1N NaOH solution (27ml) was added slowly. After stirring for another 4 hours, the organic phase was isolated and dried over sodium sulfate. The product was purified on silica (CH₂Cl₂/MeOH 98:2 then 98:4). The yield was 6.43g (9.72mmol, 79%) of a thick greenish oil. Anal. (C₂₈H₃₃I₂NO₅) C, H, N, I: calculated 46.88, 4.64, 1.95, 35.38; found 46.91, 4.66, 1.91, 35.49.

(S) - (3 - Methyl) - 2 butyl 2 - [3 - (3 , 5 - diiodo - 4 - (2 - diethylaminoethoxy)benzoyl)]benzo-furaneacetate (10d). Compound 9d (6.9g, 12.3mmol) was dissolved in CH₂Cl₂ (50ml) and was added to a solution of diethylaminoethyl chloride, hydrochloride (2.55g, 14.8mmol) and benzyltriethylammonium chloride (0.28g, 1.23mmol) in water (50ml). The biphasic medium was stirred vigorously and a 1N NaOH solution (27ml) was added slowly. After stirring for another 4 hours, the organic phase was isolated and dried over sodium sulfate.

The product was purified on silica (CH₂Cl₂/MeOH 98:2 then 98:4). The yield was 6.43g (9.72mmol, 79%) of a thick greenish oil. Anal. (C₂₈H₃₃I₂NO₅) C, H, N, I: calculated 46.88, 4.64, 1.95, 35.38; found 46.93, 4.62, 1.89, 35.54.

Formulation as a sulfate salt in water. To compound **10a** (3.31g, 5mmol.) was added water (200 ml) and 1N sulfuric acid (5.0ml). The mixture was stirred until a clear solution was obtained. The solution was extracted twice with 50-ml portions of methylene chloride. The extracts were dried over sodium sulfate, filtered, and evaporated in a precisely weighed flask to give a yellow oil. The product was dried *under vacuum* at room temperature for 2 hours. Water was then added (about 250 ml) to the flask in order to make a 20-mmol/ml solution of **10a**, sulfate salt. All the compounds in this series were formulated in a similar way. The pH of the solutions was typically 4.8 to 5.0. Compounds **10b**, **10c**, and **10d** were formulated in a similar manner. An exemplary synthesis pathway is provided in Figures 13A-B.


It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.

25

Claims

We claim:

1. A compound, or a pharmaceutically acceptable salt thereof, wherein said compound has the formula:



wherein

X₁ and X₂ may be the same or different and are selected from the group consisting of iodine, fluorine, bromine, and chlorine;


m is from 0-10;

R₁ is selected from the group consisting of H, C_{n-20} alkyl, C₂₋₂₀ alkenyl, aryl, C₁₋₂₀ alkyl-aryl, C₂₋₂₀ alkenyl-aryl, heteroaryl, C₁₋₂₀ alkyl-heteroaryl, C₂₋₂₀ alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C₁₋₂₀ alkyl-heterocycloalkyl, and C₁₋₂₀ alkyl-cycloalkyl, any of which may be, optionally, substituted with a moiety selected from the group consisting of C₁₋₆ alkyl, halogen, CN, NO₂, and SO₂₋₄;

n is one; and

wherein said compound is in at least about 90% enantiomeric excess.


2. The compound, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein said compound has the formula:



(10b, S-2042)

1 3. The pharmaceutically acceptable salt, according to claim 1, wherein said salt
2 is a sulfate salt.

1 4. A composition comprising a compound, or a pharmaceutically acceptable salt
2 thereof, wherein said compound has the formula:



4 X₁ and X₂ may be the same or different and are selected from the group consisting
5 of iodine, fluorine, bromine, and chlorine;


7 R₁ is selected from the group consisting of H, C_{n-20} alkyl, C₂₋₂₀ alkenyl, aryl, C₁₋₂₀
8 alkyl-aryl, C₂₋₂₀ alkenyl-aryl, heteroaryl, C₁₋₂₀ alkyl-heteroaryl, C₂₋₂₀ alkenyl-heteroaryl,
9 cycloalkyl, heterocycloalkyl, C₁₋₂₀ alkyl-heterocycloalkyl, and C₁₋₂₀ alkyl-cycloalkyl, any
10 of which may be, optionally, substituted with a moiety selected from the group consisting
11 of C₁₋₆ alkyl, halogen, CN, NO₂, and SO₂₋₄;

13 wherein said compound is in at least about 90% enantiomeric excess; and a
14 pharmaceutically acceptable carrier.

1 5. The composition, according to claim 4, which comprises a compound, or a
2 pharmaceutically acceptable salt thereof, wherein said compound has the formula:

27


3 (10b, S-2042)



4 wherein said compound is in at least about 90% enantiomeric excess.

1 6. The composition, according to claim 4, wherein said pharmaceutically
2 acceptable salt is a sulfate salt.

1 7. A method of treating or reducing the incidence of cardiac arrhythmias
2 comprising the administration to an individual of a therapeutically effective amount of
3 a compound, or a pharmaceutically acceptable salt thereof, wherein said compound has
4 the formula:



5 wherein


6 X_1 and X_2 may be the same or different and are selected from the group consisting
7 of iodine, fluorine, bromine, and chlorine;

8 m is from 0-10;

9 R_1 is selected from the group consisting of H, C_{n-20} alkyl, C_{2-20} alkenyl, aryl, C_{1-20}
10 alkyl-aryl, C_{2-20} alkenyl-aryl, heteroaryl, C_{1-20} alkyl-heteroaryl, C_{2-20} alkenyl-heteroaryl,
11 cycloalkyl, heterocycloalkyl, C_{1-20} alkyl-heterocycloalkyl, and C_{1-20} alkyl-cycloalkyl, any
12 of which may be, optionally, substituted with a moiety selected from the group consisting
13 of C_{1-6} alkyl, halogen, CN, NO_2 , and $SO_{2,4}$;

14 n is one; and
15 wherein said compound is in at least about 90% enantiomeric excess.

1 8. The method, according to claim 7, of treating or reducing the incidence of
2 cardiac arrhythmias comprising the administration to an individual of a therapeutically
3 effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein
4 said compound has the formula:



5 (10b, S-2042)
6 and wherein said compound is in at least about 90% enantiomeric excess.

1 9. The method of claim 7, wherein said cardiac arrhythmia is selected from the
2 group consisting of atrial fibrillation, flutter, paroxysmal supraventricular tachycardia,
3 ventricular premature beats and ventricular tachycardia.

1 10. The method of claim 7, further comprising the administration of additional
2 compounds.


1 11. The method of claim 7, wherein said individual is a high risk cardiac patient.

1 12. The method of claim 11, wherein said patient is a post-myocardial infarction
2 patient.

1 13. The method of claim 11, wherein said patient has congestive heart failure.

1 14. The method, according to claim 7, wherein said pharmaceutically acceptable
2 salt is a sulfate salt.

1 15. A compound, or a pharmaceutically acceptable salt thereof, wherein said
2 compound has the formula:



3 wherein

4 X_1 and X_2 may be the same or different and are selected from the group consisting
5 of iodine, fluorine, bromine, and chlorine;


6 m is from 0-10;

7 R_2 and R_3 may be the same or different and are each selected from the group
8 consisting of C_{n-20} alkyl, C_{2-20} alkenyl, aryl, C_{1-20} alkyl-aryl, C_{2-20} alkenyl-aryl, heteroaryl,
9 C_{1-20} alkyl-heteroaryl, C_{2-20} alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C_{1-20} alkyl-
10 heterocycloalkyl, and C_{1-20} alkyl-cycloalkyl, any of which may be, optionally, substituted
11 with a moiety selected from the group consisting of C_{1-6} alkyl, halogen, CN, NO_2 , and
12 SO_{2-4} ;

13 n is at least one; and

14 wherein said compound is in at least about 90% enantiomeric excess.

1 16. The compound, or a pharmaceutically acceptable salt thereof, according to
2 claim 15, wherein said compound has the formula:




3 (10c, R-2055)

4 wherein said compound is in at least about 90% enantiomeric excess.

1 17. The pharmaceutically acceptable salt, according to claim 15, wherein said salt
2 is a sulfate salt.

1 18. A composition comprising a compound, or a pharmaceutically acceptable salt
2 thereof, wherein said compound has the formula:



3 wherein

4 X_1 and X_2 may be the same or different and are selected from the group consisting
5 of iodine, fluorine, bromine, and chlorine;

6 m is from 0-10;


7 R_2 and R_3 may be the same or different and are each selected from the group
8 consisting of C_{n-20} alkyl, C_{2-20} alkenyl, aryl, C_{1-20} alkyl-aryl, C_{2-20} alkenyl-aryl, heteroaryl,
9 C_{1-20} alkyl-heteroaryl, C_{2-20} alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C_{1-20} alkyl-
10 heterocycloalkyl, and C_{1-20} alkyl-cycloalkyl, any of which may be, optionally, substituted
11 with a moiety selected from the group consisting of C_{1-6} alkyl, halogen, CN, NO_2 , and
12 SO_{2-4} ;

13 n is at least one; and

14 wherein said compound is in at least about 90% enantiomeric excess; and a
15 pharmaceutically acceptable carrier.

1 19. The composition, according to claim 18, comprising a compound, or a
2 pharmaceutically acceptable salt thereof, wherein said compound has the formula:


3 (10c, R-2055)



4 wherein said compound is in at least about 90% enantiomeric excess.

1 20. The composition, according to claim 18, wherein said pharmaceutically
2 acceptable salt is a sulfate salt.

1 21. A method of treating or reducing the incidence of cardiac arrhythmias
2 comprising the administration to an individual of a therapeutically effective amount of
3 a compound, or a pharmaceutically acceptable salt thereof, wherein said compound has
4 the formula:



5 wherein

6 X₁ and X₂ may be the same or different and are selected from the group consisting
7 of iodine, fluorine, bromine, and chlorine;

8 m is from 0-10;

9 R₂ and R₃ may be the same or different and are each selected from the group
10 consisting of C_{n-20} alkyl, C₂₋₂₀ alkenyl, aryl, C₁₋₂₀ alkyl-aryl, C₂₋₂₀ alkenyl-aryl, heteroaryl,
11 C₁₋₂₀ alkyl-heteroaryl, C₂₋₂₀ alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C₁₋₂₀ alkyl-
12 heterocycloalkyl, and C₁₋₂₀ alkyl-cycloalkyl, any of which may be, optionally, substituted
13 with a moiety selected from the group consisting of C₁₋₆ alkyl, halogen, CN, NO₂, and
14 SO₂₋₄;


15 n is at least one; and

16 wherein said compound is in at least about 90% enantiomeric excess.

1 22. The method, according to claim 21, of treating or reducing the incidence of
2 cardiac arrhythmias comprising the administration to an individual of a therapeutically
3 effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein
4 said compound has the formula:

32

5 (10c, R-2055)



6 wherein said compound is in at least about 90% enantiomeric excess.

1 23. The method of claim 21, wherein said cardiac arrhythmia is selected from the
 2 group consisting of atrial fibrillation, flutter, paroxysmal supraventricular tachycardia,
 3 ventricular premature beats and ventricular tachycardia.

1 24. The method of claim 21, further comprising the administration of an
 2 additional compound.


1 25. The method of claim 21, wherein said individual is a high risk cardiac
 2 patient.

1 26. The method of claim 25, wherein said patient is a post-myocardial infarction
 2 patient.

1 27. The method of claim 25, wherein said patient has congestive heart failure.

1 28. The method of claim 21, wherein said pharmaceutically acceptable salt is a
 2 sulfate salt.


1 29. A compound, or a pharmaceutically acceptable salt thereof, wherein said
 2 compound has the formula:



31. The pharmaceutically acceptable salt, according to claim 29, wherein said salt is a sulfate salt.

34

1 32. A composition comprising a compound, or a pharmaceutically acceptable salt
2 thereof, wherein said compound has the formula:



3 wherein

4 X₁ and X₂ may be the same or different and are selected from the group consisting
5 of iodine, fluorine, bromine, and chlorine;

6 m is from 0-10;


7 R₁ is selected from the group consisting of C_{n-20} alkyl, C₂₋₂₀ alkenyl, aryl, C₁₋₂₀
8 alkyl-aryl, C₂₋₂₀ alkenyl-aryl, heteroaryl, C₁₋₂₀ alkyl-heteroaryl, C₂₋₂₀ alkenyl-heteroaryl,
9 cycloalkyl, heterocycloalkyl, C₁₋₂₀ alkyl-heterocycloalkyl, and C₁₋₂₀ alkyl-cycloalkyl, any
10 of which may be, optionally, substituted with a moiety selected from the group consisting
11 of C₁₋₆ alkyl, halogen, CN, NO₂, and SO₂₋₄;

12 n is at least one; and

13 wherein said compound is in at least about 90% enantiomeric excess; and
14 a pharmaceutically acceptable carrier.

1 33. The composition, according to claim 32, comprising a compound, or a
2 pharmaceutically acceptable salt thereof, wherein said compound has the formula:


3 (10a, R-2042)



4 wherein said compound is in at least about 90% enantiomeric excess.

34. The composition, according to claim 32, wherein said pharmaceutically acceptable salt is a sulfate salt.

35. A method of treating or reducing the incidence of cardiac arrhythmias comprising the administration to an individual of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein said compound has the formula:



wherein

X₁ and X₂ may be the same or different and are selected from the group consisting of iodine, fluorine, bromine, and chlorine;

m is from 0-10;

R₁ is selected from the group consisting of C_{n-20} alkyl, C₂₋₂₀ alkenyl, aryl, C₁₋₂₀ alkyl-aryl, C₂₋₂₀ alkenyl-aryl, heteroaryl, C₁₋₂₀ alkyl-heteroaryl, C₂₋₂₀ alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C₁₋₂₀ alkyl-heterocycloalkyl, and C₁₋₂₀ alkyl-cycloalkyl, any of which may be, optionally, substituted with a moiety selected from the group consisting of C₁₋₆ alkyl, halogen, CN, NO₂, and SO₂₋₄;


n is at least one; and

wherein said compound is in at least about 90% enantiomeric excess.

36

1 36. The method, according to claim 35, of treating or reducing the incidence of
2 cardiac arrhythmias comprising the administration to an individual of a therapeutically
3 effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein
4 said compound has the formula:

5 (10a, R-2042)



6 wherein said compound is in at least about 90% enantiomeric excess.

1 37. The method of claim 35, wherein said cardiac arrhythmia is selected from the
2 group consisting of atrial fibrillation, flutter, paroxysmal supraventricular tachycardia,
3 ventricular premature beats and ventricular tachycardia.

1 38. The method of claim 35, further comprising the administration of additional
2 compounds.

1 39. The method of claim 35, wherein said individual is a high risk cardiac
2 patient.


1 40. The method of claim 39, wherein said patient is a post-myocardial infarction
2 patient.

1 41. The method of claim 39, wherein said patient has congestive heart failure.

1 42. The method according to claim 35, wherein said pharmaceutically acceptable
2 salt is a sulfate salt.

37

43. A compound, or a pharmaceutically acceptable salt thereof, wherein said compound has the formula:



wherein

X_1 and X_2 may be the same or different and are selected from the group consisting of iodine, fluorine, bromine, and chlorine;


m is from 0-10;

R_2 and R_3 may be the same or different and are selected from the group consisting of C_{n-20} alkyl, C_{2-20} alkenyl, aryl, C_{1-20} alkyl-aryl, C_{2-20} alkenyl-aryl, heteroaryl, C_{1-20} alkyl-heteroaryl, C_{2-20} alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C_{1-20} alkyl-heterocycloalkyl, and C_{1-20} alkyl-cycloalkyl, any of which may be, optionally, substituted with a moiety selected from the group consisting of C_{1-6} alkyl, halogen, CN, NO_2 , and SO_{2-4} ;

n is one; and

wherein said compound is in at least about 90% enantiomeric excess.

44. The compound, or a pharmaceutically acceptable salt thereof, according to claim 43, wherein said compound has the formula:




(10d, S-2055)

wherein said compound is in at least about 90% enantiomeric excess.

1 45. The pharmaceutically acceptable salt according to claim 43, wherein said salt
2 is a sulfate salt.

1 46. A composition comprising a compound, or a pharmaceutically acceptable salt
2 thereof, wherein said compound has the formula:



3 wherein

4 X₁ and X₂ may be the same or different and are selected from the group consisting
5 of iodine, fluorine, bromine, and chlorine;

6 m is from 0-10;

7 R₂ and R₃ may be the same or different and are selected from the group consisting
8 of C_{n-20} alkyl, C₂₋₂₀ alkenyl, aryl, C₁₋₂₀ alkyl-aryl, C₂₋₂₀ alkenyl-aryl, heteroaryl, C₁₋₂₀ alkyl-
9 heteroaryl, C₂₋₂₀ alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C₁₋₂₀ alkyl-
10 heterocycloalkyl, and C₁₋₂₀ alkyl-cycloalkyl, any of which may be, optionally, substituted
11 with a moiety selected from the group consisting of C₁₋₆ alkyl, halogen, CN, NO₂, and
12 SO₂₋₄;

13 n is one; and


14 wherein said compound is in at least about 90% enantiomeric excess; and a
15 pharmaceutically acceptable carrier.

1 47. The composition, according to claim 46, comprising a compound, or a
2 pharmaceutically acceptable salt thereof, wherein said compound has the formula:

39

3

(10d, S-2055)



4

wherein said compound is in at least about 90% enantiomeric excess.

1

48. The composition according to claim 46, wherein said pharmaceutically

2

acceptable salt is a sulfate salt.

3

49. A method of treating or reducing the incidence of cardiac arrhythmias

4


comprising the administration to an individual of a therapeutically effective amount of

5

a compound, or a pharmaceutically acceptable salt thereof, wherein said compound has

6

the formula:



7

wherein

8

X_1 and X_2 may be the same or different and are selected from the group consisting

9

of iodine, fluorine, bromine, and chlorine;

10

m is from 0-10;

11

R_2 and R_3 may be the same or different and are selected from the group consisting

12

of C_{n-20} alkyl, C_{2-20} alkenyl, aryl, C_{1-20} alkyl-aryl, C_{2-20} alkenyl-aryl, heteroaryl, C_{1-20} alkyl-

13

heteroaryl, C_{2-20} alkenyl-heteroaryl, cycloalkyl, heterocycloalkyl, C_{1-20} alkyl-

14

heterocycloalkyl, and C_{1-20} alkyl-cycloalkyl, any of which may be, optionally, substituted


40

with a moiety selected from the group consisting of C₁₋₆ alkyl, halogen, CN, NO₂, and SO₂₋₄;

n is one; and

wherein said compound is in at least about 90% enantiomeric excess.

50. The method, according to claim 49, of treating or reducing the incidence of cardiac arrhythmias comprising the administration to an individual of a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein said compound has the formula:



(10d, S-2055)

wherein said compound is in at least about 90% enantiomeric excess.

51. The method of claim 49, wherein said cardiac arrhythmia is selected from the group consisting of atrial fibrillation, flutter, paroxysmal supraventricular tachycardia, ventricular premature beats and ventricular tachycardia.

52. The method of claim 49, further comprising the administration of additional compounds.


53. The method of claim 49, wherein said individual is a high risk cardiac patient.

54. The method of claim 53, wherein said patient is a post-myocardial infarction patient.

1 55. The method of claim 53, wherein said patient has congestive heart failure.

1 56. The method according to claim 49, wherein said pharmaceutically acceptable
2 salt is a sulfate salt.

1/16

**amiodarone****FIG. 1**

2/16




FIG. 2




FIG. 3




FIG. 4




FIG. 5

6/16




FIG. 6

7/16




FIG. 7




FIG. 8




FIG. 9




FIG. 10

11/16




FIG. 11

12/16




FIG. 12

13/16




FIG. 13A




FIG. 13B

15/16




FIG. 14




FIG. 15




FIG. 16




FIG. 17

16/16




FIG. 18




FIG. 19




FIG. 20




FIG. 21

